Video

Shoshana Lipson on the Patient Perception of CGRP Inhibitors

Shoshana Lipson, a patient advocate and founder of the “CGRP & Migraine Community ” on Facebook explains the patient perspective of CGRP inhibitors.

Shoshana Lipson, a patient advocate and founder of the “CGRP & Migraine Community ” on Facebook explains the patient perspective of CGRP inhibitors.

Transcript:

Are patients knowledgeable about [calcitonin gene-related peptide] CGRP inhibitors?

So, I would say it is kind of a mixed bag in terms of knowledge about the CGRP medications. Some people are very knowledgeable; they knew that they were coming, they had it planned, I personally had my doctor’s appointment set around a week after the first medication was approved. I knew it was coming and I knew I wanted to try it.

But then you’ve got people on the other end of the spectrum who are still saying “What? What’s CGRP and what does that stand for, what does it do, does this actually potentially help someone who has migraine?” So, we have the full range of the spectrum, and then again, trying to take that information and put it into simple language is just really, really crucial. So, we not only have my support group, but there are obviously also posts in the other migraine groups, but I’m also writing articles and speaking at different places just to educate patients about these new medications and also what they’re like in real-world application.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Martin Engelke
David Awad, PharmD, BCOP
Dr Adela Perolla
Dr Adela Perolla | Image Credit: - stock.adobe.com
Dr Ola Landgren
Dr Ola Landgren
Andrew Kuykendall, MD, Moffitt Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Dirk Arnold, MD, PhD, medical director, Asklepios Tumour Biology Centre
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo